Navigation Links
Takeda Drives Leading PAMES Study in Brazil Showing Improved Symptom Relief for People with Erosive Gastroesophageal Reflux Disease (GERD)
Date:12/12/2013

p>]

Common symptoms of reflux disease are persistent heartburn and regurgitation, i.e. pain or burning in the chest, stomach acid rising into the oesophagus, sour taste in the mouth and burning in the throat. The prevalence of GERD has increased over the last 20 years.[7],[8]

About Tecta®

Tecta® (pantoprazole magnesium) is a proton pump inhibitor used for the treatment of reflux esophagitis, gastric and duodenal ulcers, Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.

Takeda has a long heritage of focusing on bringing relief to patients affected by having to live with upper gastrointestinal disorders through the development of innovative treatments and through professional partnerships that support efforts to educate the medical and patient communities.

Other PPIs marketed by the Takeda Group include: Pantoprazole sodium available in more than 90 countries under a variety of brand names and formulations, including Pantozol®, Somac®, Controloc®, Pantoloc® and Zurcal®. In the US, Pantoprazole sodium is marketed by Takeda's partner, Pfizer Inc., under the brand name Protonix®. Prevacid® (lansoprazole) is a well-known PPI in around 90 markets, and Dexilant (dexlansoprazole), the first PPI with a novel dual delayed release technology.

About Takeda Pharmaceuticals International GmbH

Headquartered in Zurich as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, the company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including La
'/>"/>

SOURCE Takeda Pharmaceuticals International GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Advisory Committee Recommends Approval of Takedas Investigational Biologic Vedolizumab
2. Takedas Deerfield Campus Among Chicago Tribunes 2013 Top 100 Workplaces
3. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
4. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
5. Takeda Cares Day Raises $63,700
6. Takedas Deerfield Campus Ranked Among 2013 Working Mother 100 Best Companies
7. Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto lendpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
8. Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
9. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
10. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
11. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Calif. , June 14 The ... directly to cancer sites with minimal exposure to ... multiple publications, according to Xoft, Inc., developer of ... provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides ...
... of the Pros & Cons of Robotic Surgery , ... PHILADELPHIA , June 11 Robotic surgery -- is it ... campaigns and targeted marketing to physicians? , , ... robots help surgeons perform surgery with greater access, visibility and precision all which reduce ...
Cached Medicine Technology:Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 2Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 3Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 4Robotic Surgery: Medicine or Marketing? 2Robotic Surgery: Medicine or Marketing? 3Robotic Surgery: Medicine or Marketing? 4Robotic Surgery: Medicine or Marketing? 5
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see ... becomes a serious challenge. Because of growing competition, it is more important than ... community. , The team at Wound Care Advantage has found that ...
(Date:7/30/2015)... ... July 30, 2015 , ... The connection between a healthy head of hair and ... loss of a full head of hair can have a devastating impact on the daily ... perceived in the work place, the consequences of hair loss are not to be taken ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. ...
(Date:7/30/2015)... San Diego, CA (PRWEB) , ... July 30, ... ... company has been consistently growing into one of the largest, family-owned low cost ... offered across residential and commercial applications, as well as growing their company to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... its position as one of Medicare’s top-rated care centers. The video highlights ... CMS rating system, which monitors health inspections, staffing, and quality measures. Beachside ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Beachside Nursing Center Releases New Video 2
... Aiming to increase its presence in the Indian market and ... to add a punch of health// to its India portfolio, ... at offering total beverage solutions in the non-alcohol segment. This ... health-based products,’ Coca Cola India chief Atul Singh told PTI ...
... Washington – Dutch research into child cancer survivors has revealed ... are twice as much compared// to those without a history ... survivors, those that have survived brain cancer or other central ... of remaining jobless. The Children, who came out of blood-cell ...
... children who are exposed to cats soon after birth face ... causes the skin// to become red, scaly and itchy. This ... on May 21st. , ,Being exposed to two ... not significant, effect on children's risk of developing eczema, said ...
... have announced that, they are taking preventive steps with as ... past three months//. ,A senior health official ... visit Tripura to assess the situation and to provide expert ... also stated that almost 200 teams, consisting of health workers ...
... doctors of Sir Sunderlal hospital in the Banaras Hindu University ... day today to protest against the proposed 27 per cent ... ,Apart from the relay hunger strike, the agitating ... out mass mobilisation campaign on the issue at the Assi ...
... one study it was said that 44 % of women ... affects both the mental health as well as the physical ... senior investigators of the Group Health Center for Health Studies, ... researchers found that nearly half -44 per cent, reported having ...
Cached Medicine News:Health News:Children Having An Early Exposure To Cats May Develop Eczema 2
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
Inquire...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
Inquire...
Medicine Products: